KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Gross Margin: 2017-2025

Historic Gross Margin for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to 79.63%.

  • Moderna's Gross Margin rose 723.00% to 79.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 48.25%, marking a year-over-year decrease of 1877.00%. This contributed to the annual value of 54.76% for FY2024, which is 2329.00% up from last year.
  • Moderna's Gross Margin amounted to 79.63% in Q3 2025, which was up 391.60% from 16.20% recorded in Q2 2025.
  • In the past 5 years, Moderna's Gross Margin registered a high of 90.04% during Q1 2021, and its lowest value of -112.50% during Q2 2023.
  • For the 3-year period, Moderna's Gross Margin averaged around 25.01%, with its median value being 34.66% (2024).
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by 18,342bps in 2023, then skyrocketed by 14,716bps in 2024.
  • Quarterly analysis of 5 years shows Moderna's Gross Margin stood at 86.80% in 2021, then plummeted by 2,452bps to 62.27% in 2022, then skyrocketed by 468bps to 66.95% in 2023, then slumped by 4,345bps to 23.50% in 2024, then surged by 723bps to 79.63% in 2025.
  • Its Gross Margin stands at 79.63% for Q3 2025, versus 16.20% for Q2 2025 and 16.67% for Q1 2025.